Emapalumab Biosimilar

Emapalumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IFNG, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. 1, 5 The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy. 5 As well, emapalumab was given the status of PRIME by the EMA.

Target	IFNG
Research Area	Biosimilars
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG1 Lambda
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles.
Shelf Life	12 months.
Buffer	0.01 M PBS, pH 7.4.
CAS Number	1709815-23-5
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 5-10 working days.
Note	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Research Articles on IFNG

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue